The Journal of Heart and Lung Transplantation
Volume 29, Issue 9 , Pages 997-1008 , September 2010

Systemic and exhaled cytokine and chemokine profiles are associated with the development of bronchiolitis obliterans syndrome

  • Elisabeth A. Kastelijn, MD

      Affiliations

    • Centre of Interstitial Lung Diseases, Department of Pulmonology, St Antonius Hospital, The Netherlands
    • ,
  • Ger T. Rijkers, PhD

      Affiliations

    • Department of Medical Microbiology and Immunology, St Antonius Hospital, The Netherlands
    • ,
  • Coline H.M. Van Moorsel, PhD

      Affiliations

    • Centre of Interstitial Lung Diseases, Department of Pulmonology, St Antonius Hospital, The Netherlands
    • ,
  • Pieter Zanen, MD

      Affiliations

    • Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht, The Netherlands
    • ,
  • Johanna M. Kwakkel-van Erp, MD

      Affiliations

    • Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht, The Netherlands
    • ,
  • Ed A. Van De Graaf, MD, PhD

      Affiliations

    • Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht, The Netherlands
    • ,
  • Diana A. Van Kessel, MD

      Affiliations

    • Centre of Interstitial Lung Diseases, Department of Pulmonology, St Antonius Hospital, The Netherlands
    • ,
  • Jan C. Grutters, MD, PhD

      Affiliations

    • Centre of Interstitial Lung Diseases, Department of Pulmonology, St Antonius Hospital, The Netherlands
    • Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht, The Netherlands
    • Corresponding Author InformationReprint requests: Jan C. Grutters, MD, PhD, St. Antonius Hospital, Postbox 2500, 3420 EM Nieuwegein, The Netherlands. Telephone: +31-0-30-609-2428. Fax: +31-0-30-605-2001
    • ,
  • Jules M.M. Van Den Bosch, MD, PhD

      Affiliations

    • Centre of Interstitial Lung Diseases, Department of Pulmonology, St Antonius Hospital, The Netherlands
    • Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht, The Netherlands

References 

  1. Boehler A, Kesten S, Weder W, Speich R. Bronchiolitis obliterans after lung transplantation: a review. Chest. 1998;114:1411–1426
  2. Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med. 2002;166:440–444
  3. Verleden GM. Chronic allograft rejection (obliterative bronchiolitis). Semin Respir Crit Care Med. 2001;22:551–558
  4. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant. 2007;26:1229–1242
  5. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002;21:297–310
  6. Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med. 2002;166:440–444
  7. Knoop C, Estenne M. Acute and chronic rejection after lung transplantation. Semin Respir Crit Care Med. 2006;27:521–533
  8. Nicod LP. Mechanisms of airway obliteration after lung transplantation. Proc Am Thorac Soc. 2006;3:444–449
  9. Belperio JA, Lake K, Tazelaar H, Keane MP, Strieter RM, Lynch JP. Bronchiolitis obliterans syndrome complicating lung or heart-lung transplantation. Semin Respir Crit Care Med. 2003;24:499–530
  10. Belperio JA, Weigt SS, Fishbein MC, Lynch JP. Chronic lung allograft rejection: mechanisms and therapy. Proc Am Thorac Soc. 2009;6:108–121
  11. Hodge G, Hodge S, Chambers D, Reynolds PN, Holmes M. Bronchiolitis obliterans syndrome is associated with absence of suppression of peripheral blood Th1 proinflammatory cytokines. Transplantation. 2009;88:211–218
  12. Bharat A, Narayanan K, Street T, et al. Early posttransplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplantation. 2007;83:150–158
  13. Zhai Y, Ghobrial RM, Busuttil RW, Kupiec-Weglinski JW. Th1 and Th2 cytokines in organ transplantation: paradigm lost?. Crit Rev Immunol. 1999;19:155–172
  14. Beauregard C, Stevens C, Mayhew E, Niederkorn JY. Cutting edge: atopy promotes Th2 responses to alloantigens and increases the incidence and tempo of corneal allograft rejection. J Immunol. 2005;174:6577–6581
  15. Keane MP, Gomperts BN, Weigt S, et al. IL-13 is pivotal in the fibro-obliterative process of bronchiolitis obliterans syndrome. J Immunol. 2007;178:511–519
  16. Uboldi de CM, Dametto E, Fasano ME, et al. Cytokines and chronic rejection: a study in kidney transplant long-term survivors. Transplantation. 2004;77:548–552
  17. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med. 2001;163:1693–1722
  18. Gessner C, Scheibe R, Wotzel M, et al. Exhaled breath condensate cytokine patterns in chronic obstructive pulmonary disease. Respir Med. 2005;99:1229–1240
  19. Bucchioni E, Kharitonov SA, Allegra L, Barnes PJ. High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir Med. 2003;97:1299–1302
  20. Wechsler ME, Grasemann H, Deykin A, et al. Exhaled nitric oxide in patients with asthma: association with NOS1 genotype. Am J Respir Crit Care Med. 2000;162:2043–2047
  21. Montuschi P, Kharitonov SA, Barnes PJ. Exhaled carbon monoxide and nitric oxide in COPD. Chest. 2001;120:496–501
  22. Montuschi P, Collins JV, Ciabattoni G, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med. 2000;162:1175–1177
  23. Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. Lancet. 1994;343:133–135
  24. Stirling RG, Kharitonov SA, Campbell D, et al. Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids (Asthma and Allergy Group). Thorax. 1998;53:1030–1034
  25. Van MA, Knoop C, Estenne M. Early detection of chronic pulmonary allograft dysfunction by exhaled biomarkers. Am J Respir Crit Care Med. 2007;175:731–736
  26. Brugiere O, Thabut G, Mal H, et al. Exhaled NO may predict the decline in lung function in bronchiolitis obliterans syndrome. Eur Respir J. 2005;25:813–819
  27. Fisher AJ, Gabbay E, Small T, Doig S, Dark JH, Corris PA. Cross sectional study of exhaled nitric oxide levels following lung transplantation. Thorax. 1998;53:454–458
  28. Gabbay E, Walters EH, Orsida B, et al. Post-lung transplant bronchiolitis obliterans syndrome (BOS) is characterized by increased exhaled nitric oxide levels and epithelial inducible nitric oxide synthase. Am J Respir Crit Care Med. 2000;162:2182–2187
  29. Dupont LJ, Dewandeleer Y, Vanaudenaerde BM, Van Raemdonck DE, Verleden GM. The pH of exhaled breath condensate of patients with allograft rejection after lung transplantation. Am J Transplant. 2006;6:1486–1492
  30. Horvath I, Hunt J, Barnes PJ, et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J. 2005;26:523–548
  31. Singer JD, Willet JB. Applied longitudinal data analysis: modeling change and event occurrence. New York: Oxford University Press; 2003;
  32. Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2005;24:1454–1459
  33. Kastelijn EA, van Moorsel CH, Rijkers GT, et al. Polymorphisms in the innate immunity associated with the development of BOS after lung transplantation. J Heart Lung Transplant. 2010;in press
  34. Mamessier E, Lorec AM, Thomas P, Badier M, Magnan A, Reynaud-Gaubert M. T regulatory cells in stable posttransplant bronchiolitis obliterans syndrome. Transplantation. 2007;84:908–916
  35. Lang T, Krams SM, Berquist W, Cox KL, Esquivel CO, Martinez OM. Elevated biliary interleukin 5 as an indicator of liver allograft rejection. Transpl Immunol. 1995;3:291–298
  36. Martinez OM, Ascher NL, Ferrell L, et al. Evidence for a nonclassical pathway of graft rejection involving interleukin 5 and eosinophils. Transplantation. 1993;55:909–918
  37. Hoffman SA, Wang L, Shah CV, et al. Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation. Am J Transplant. 2009;9:389–396
  38. Davidson C, Verma ND, Robinson CM, et al. IL-13 prolongs allograft survival: association with inhibition of macrophage cytokine activation. Transpl Immunol. 2007;17:178–186
  39. Paantjens AW, Kwakkel-van Erp JM, van Ginkel WG, et al. Serum thymus and activation regulated chemokine levels post-lung transplantation as a predictor for the bronchiolitis obliterans syndrome. Clin Exp Immunol. 2008;154:202–208
  40. Meyer KC, Cardoni AL, Xiang Z, Cornwell RD, Love RB. Vascular endothelial growth factor in human lung transplantation. Chest. 2001;119:137–143
  41. Tay SS, Plain KM, Bishop GA. Role of IL-4 and Th2 responses in allograft rejection and tolerance. Curr Opin Organ Transplant. 2009;14:16–22
  42. Piccotti JR, Chan SY, VanBuskirk AM, Eichwald EJ, Bishop DK. Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival?. Transplantation. 1997;63:619–624
  43. Chen N, Gao Q, Field EH. Prevention of Th1 response is critical for tolerance. Transplantation. 1996;61:1076–1083
  44. Gao Q, Chen N, Rouse TM, Field EH. The role of interleukin-4 in the induction phase of allogeneic neonatal tolerance. Transplantation. 1996;62:1847–1854
  45. He XY, Chen J, Verma N, Plain K, Tran G, Hall BM. Treatment with interleukin-4 prolongs allogeneic neonatal heart graft survival by inducing T helper 2 responses. Transplantation. 1998;65:1145–1152
  46. Ke B, Shen XD, Lassman CR, Gao F, Busuttil RW, Kupiec-Weglinski JW. Cytoprotective and antiapoptotic effects of IL-13 in hepatic cold ischemia/reperfusion injury are heme oxygenase-1 dependent. Am J Transplant. 2003;3:1076–1082
  47. Ke B, Ritter T, Kato H, et al. Regulatory cells potentiate the efficacy of IL-4 gene transfer by up-regulating Th2-dependent expression of protective molecules in the infectious tolerance pathway in transplant recipients. J Immunol. 2000;164:5739–5745
  48. Sriram U, Biswas C, Behrens EM, et al. IL-4 suppresses dendritic cell response to type I interferons. J Immunol. 2007;179:6446–6455
  49. Webb DC, Cai Y, Matthaei KI, Foster PS. Comparative roles of IL-4, IL-13, and IL-4Ralpha in dendritic cell maturation and CD4+ Th2 cell function. J Immunol. 2007;178:219–227
  50. Fujisawa T, bu-Ghazaleh R, Kita H, Sanderson CJ, Gleich GJ. Regulatory effect of cytokines on eosinophil degranulation. J Immunol. 1990;144:642–646
  51. de Groen PC, Kephart GM, Gleich GJ, Ludwig J. The eosinophil as an effector cell of the immune response during hepatic allograft rejection. Hepatology. 1994;20:654–662
  52. Nolan CR, Saenz KP, Thomas CA, Murphy KD. Role of the eosinophil in chronic vascular rejection of renal allografts. Am J Kidney Dis. 1995;26:634–642
  53. Le MA, Flamand V, Demoor FX, et al. Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection. J Clin Invest. 1999;103:1659–1667
  54. Goldman M, Le MA, Braun M, Flamand V, Abramowicz D. A role for eosinophils in transplant rejection. Trends Immunol. 2001;22:247–251
  55. Johnson TR, Rothenberg ME, Graham BS. Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein. J Leukoc Biol. 2008;84:748–759
  56. Emad A, Emad Y. Relationship between eosinophilia and levels of chemokines (CCL5 and CCL11) and IL-5 in bronchoalveolar lavage fluid of patients with mustard gas-induced pulmonary fibrosis. J Clin Immunol. 2008;28:298–305
  57. Yamada H, Yamaguchi M, Yamamoto K, et al. Eotaxin in induced sputum of asthmatics: relationship with eosinophils and eosinophil cationic protein in sputum. Allergy. 2000;55:392–397
  58. Malmstrom NK, Kallio EA, Rintala JM, et al. Vascular endothelial growth factor in chronic rat allograft nephropathy. Transpl Immunol. 2008;19:136–144
  59. Brown KR, England KM, Goss KL, Snyder JM, Acarregui MJ. VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. Am J Physiol Lung Cell Mol Physiol. 2001;281:L1001–L1010
  60. Krebs R, Tikkanen JM, Nykanen AI, et al. Dual role of vascular endothelial growth factor in experimental obliterative bronchiolitis. Am J Respir Crit Care Med. 2005;171:1421–1429
  61. Doherty T, Broide D. Cytokines and growth factors in airway remodeling in asthma. Curr Opin Immunol. 2007;19:676–680
  62. Broide DH. Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. J Allergy Clin Immunol. 2008;121:560–570
  63. Lee CG, Link H, Baluk P, et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med. 2004;10:1095–1103
  64. Wen FQ, Liu X, Manda W, et al. TH2 Cytokine-enhanced and TGF-beta-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-gamma and corticosteroids. J Allergy Clin Immunol. 2003;111:1307–1318
  65. Corne J, Chupp G, Lee CG, et al. IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury. J Clin Invest. 2000;106:783–791
  66. Boehler A, Estenne M. Obliterative bronchiolitis after lung transplantation. Curr Opin Pulm Med. 2000;6:133–139
  67. Rosias PP, Robroeks CM, Kester A, et al. Biomarker reproducibility in exhaled breath condensate collected with different condensers. Eur Respir J. 2008;31:934–942
  68. Zheng L, Walters EH, Ward C, et al. Airway neutrophilia in stable and bronchiolitis obliterans syndrome patients following lung transplantation. Thorax. 2000;55:53–59
  69. Riise GC, Williams A, Kjellstrom C, Schersten H, Andersson BA, Kelly FJ. Bronchiolitis obliterans syndrome in lung transplant recipients is associated with increased neutrophil activity and decreased antioxidant status in the lung. Eur Respir J. 1998;12:82–88

PII: S1053-2498(10)00269-X

doi: 10.1016/j.healun.2010.04.013

The Journal of Heart and Lung Transplantation
Volume 29, Issue 9 , Pages 997-1008 , September 2010

Article Tools

* Image Usage & Resolution